mitoxantrone has been researched along with Neutropenia in 88 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cabazitaxel significantly improves overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) progressing during or after docetaxel, but is associated with a higher rate of grade ≥3 neutropenia compared with docetaxel." | 9.22 | Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial. ( de Bono, J; de Wit, R; Liewen, H; Meisel, A; Sartor, O; Stenner-Liewen, F; Vogt, DR; von Felten, S, 2016) |
| "Gemcitabine and mitoxantrone are active agents for the treatment of metastatic breast cancer." | 9.11 | Gemcitabine and mitoxantrone in metastatic breast cancer: a phase-I-study. ( Akrivakis, K; Flath, B; Heilmann, V; Kreienberg, R; Mergenthaler, HG; Possinger, K; Schmid, P; Sezer, O, 2005) |
| "This study evaluated mitoxantrone and paclitaxel combination chemotherapy in the treatment of patients with metastatic breast cancer." | 9.09 | Mitoxantrone and paclitaxel combination chemotherapy in metastatic breast cancer. ( Campbell, M; Cantrell, J; Cartmell, A; Ghalie, R; Harvey, J; Modiano, M; Newcomb, T; Rubin, A; Schuster, M; Urba, W, 2001) |
| "To intensify a regimen of high-dose cyclophosphamide, mitoxantrone, and carboplatin that had previously produced high complete and overall response rates in metastatic breast cancer (MBC)." | 9.09 | Phase I/II trial of cyclophosphamide, mitoxantrone, and escalated doses of carboplatin supported by peripheral-blood stem cells in women with metastatic breast cancer. ( Crump, M; Goss, P; Keating, A; MacKinnon, J; Nagy, T; Patnaik, A; Stewart, K, 2000) |
| "To evaluate the activity and tolerance of docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor (G-CSF) as front-line treatment in patients with metastatic breast cancer (MBC)." | 9.09 | Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study. ( Agelaki, S; Alexopoulos, A; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kosmas, C; Kouroussis, C; Malamos, N; Mavroudis, D; Rigatos, G; Sarra, E; Vlachonicolis, J, 2001) |
| "To define the maximum-tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of docetaxel in combination with mitoxantrone in patients with metastatic breast cancer (MBC)." | 9.09 | Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer. ( Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Katsogridakis, K; Kotsakis, T; Kouroussis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N; Vlachonikolis, J, 1999) |
| "A prospective, randomized, double-blind placebo-controlled trial was designed to evaluate the impact of granulocyte/macrophage-colony-stimulating factor (GM-CSF) on the efficacy of sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy (S-HAM) in adult patients with high-risk myelodysplastic syndromes (MDS)." | 9.09 | Results of a randomized double-blind placebo-controlled trial evaluating sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy with or without granulocyte/macrophage-colony-stimulating factor in high-risk myelodysplastic syndromes. ( Aul, C; Balleisen, L; Bennett, J; Büchner, T; Fonatsch, C; Haase, D; Heinecke, A; Hiddemann, W; Hinrichs, HF; Koch, P; Rowe, JM; Verbeek, W; Wörmann, B, 1999) |
| "Mitoxantrone (MTZ) and vinorelbine (VNR) have shown a good efficacy in advanced breast cancer." | 9.08 | Mitoxantrone plus vinorelbine with granulocyte-colony stimulating factor (G-CSF) support in advanced breast cancer patients. A dose and schedule finding study. ( Comella, G; Comella, P; Cremone, L; Della Volpe, N; Frasci, G; Imbriani, A; Persico, G; Salzano, F, 1995) |
| "To assess efficacy and toxicity of less toxic analogs for advanced breast cancer in elderly women, we performed a phase II study using the combination mitoxantrone (MTZ)-vinorelbine (VNR)." | 9.08 | [A phase II study with mitoxantrone-vinorelbine association in the treatment of advanced breast cancer in elderly women]. ( Bugat, R; Caunes, N; Chevreau, C; Gladieff, L; Houyau, P; Martinez, M; Mihura, J; Roché, H, 1996) |
| "60 patients with metastatic breast cancer were entered in a phase II study using folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide." | 9.07 | Folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide in metastatic breast cancer. ( Beerblock, K; de Gramont, A; Demuynck, B; Guillot, T; Krulik, M; Louvet, C; Marpeau, L; Pigné, A; Soubrane, D; Varette, C, 1993) |
| " The objective of the current study was to investigate the effects of combined fludarabine, mitoxantrone, and dexamethasone (FND) followed by interferon/dexamethasone on myelosuppression (absolute neutrophil counts), immunosuppression (CD4 and CD8 counts), and infectious complications in patients with previously untreated, Stage IV indolent lymphoma." | 7.73 | Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. ( Ayala, A; Cabanillas, F; Feng, L; Hagemeister, FB; McLaughlin, P; Rodriguez, MA; Romaguera, J; Smith, TL; Tsimberidou, AM; Younes, A, 2005) |
| "Grade 3/4 neutropenia was observed in 29 patients (58%) with four neutropenic episodes." | 6.69 | First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin. ( Agelaki, S; Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Koukourakis, M; Kourousis, C; Samonis, G; Tsiftsis, D; Vamvakas, L, 1999) |
| "All patients had advanced metastatic breast cancer and have been extensively pretreated with chemotherapy (28 patients), radiotherapy (13 patients), and hormonotherapy (24 patients)." | 6.68 | Treatment of advanced and relapsing breast cancer with a combination of paclitaxel and mitoxantrone. South-Central Hellenic Oncology Group. ( Panagos, GE, 1997) |
| "Patients with advanced breast cancer were randomised to 3M (mitozantrone 6." | 6.67 | Mitozantrone and methotrexate chemotherapy with and without mitomycin C in the treatment of advanced breast cancer: a randomised clinical trial. ( Barton, C; Bliss, JM; Bower, M; Coombes, RC; Ford, HT; Gazet, JC; Law, M; Stein, RC, 1992) |
| "A disseminated Fusarium infection due to F." | 5.39 | Refractory disseminated fusariosis by Fusarium verticillioides in a patient with acute myeloid leukaemia relapsed after allogeneic hematopoietic stem cell transplantation: a case report and literature review. ( Bartolesi, AM; Fanci, R; Pecile, P; Pini, G, 2013) |
| "Mitoxantrone is an active well-tolerated agent in the treatment of advanced breast carcinoma, but the risk of neutropenia requires careful supervision." | 5.27 | Mitoxantrone: an active new agent in the treatment of advanced breast cancer. ( Bozek, T; Pavlidis, NA; Smith, IE; Stuart-Harris, RC, 1984) |
| "Cabazitaxel significantly improves overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) progressing during or after docetaxel, but is associated with a higher rate of grade ≥3 neutropenia compared with docetaxel." | 5.22 | Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial. ( de Bono, J; de Wit, R; Liewen, H; Meisel, A; Sartor, O; Stenner-Liewen, F; Vogt, DR; von Felten, S, 2016) |
| "Gemcitabine and mitoxantrone are active agents for the treatment of metastatic breast cancer." | 5.11 | Gemcitabine and mitoxantrone in metastatic breast cancer: a phase-I-study. ( Akrivakis, K; Flath, B; Heilmann, V; Kreienberg, R; Mergenthaler, HG; Possinger, K; Schmid, P; Sezer, O, 2005) |
| "To intensify a regimen of high-dose cyclophosphamide, mitoxantrone, and carboplatin that had previously produced high complete and overall response rates in metastatic breast cancer (MBC)." | 5.09 | Phase I/II trial of cyclophosphamide, mitoxantrone, and escalated doses of carboplatin supported by peripheral-blood stem cells in women with metastatic breast cancer. ( Crump, M; Goss, P; Keating, A; MacKinnon, J; Nagy, T; Patnaik, A; Stewart, K, 2000) |
| "To define the maximum-tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of docetaxel in combination with mitoxantrone in patients with metastatic breast cancer (MBC)." | 5.09 | Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer. ( Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Katsogridakis, K; Kotsakis, T; Kouroussis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N; Vlachonikolis, J, 1999) |
| "A prospective, randomized, double-blind placebo-controlled trial was designed to evaluate the impact of granulocyte/macrophage-colony-stimulating factor (GM-CSF) on the efficacy of sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy (S-HAM) in adult patients with high-risk myelodysplastic syndromes (MDS)." | 5.09 | Results of a randomized double-blind placebo-controlled trial evaluating sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy with or without granulocyte/macrophage-colony-stimulating factor in high-risk myelodysplastic syndromes. ( Aul, C; Balleisen, L; Bennett, J; Büchner, T; Fonatsch, C; Haase, D; Heinecke, A; Hiddemann, W; Hinrichs, HF; Koch, P; Rowe, JM; Verbeek, W; Wörmann, B, 1999) |
| "This study evaluated mitoxantrone and paclitaxel combination chemotherapy in the treatment of patients with metastatic breast cancer." | 5.09 | Mitoxantrone and paclitaxel combination chemotherapy in metastatic breast cancer. ( Campbell, M; Cantrell, J; Cartmell, A; Ghalie, R; Harvey, J; Modiano, M; Newcomb, T; Rubin, A; Schuster, M; Urba, W, 2001) |
| "To evaluate the activity and tolerance of docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor (G-CSF) as front-line treatment in patients with metastatic breast cancer (MBC)." | 5.09 | Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study. ( Agelaki, S; Alexopoulos, A; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kosmas, C; Kouroussis, C; Malamos, N; Mavroudis, D; Rigatos, G; Sarra, E; Vlachonicolis, J, 2001) |
| "Prior studies of the combination of fludarabine, mitoxantrone and dexamethasone have yielded high response rates but are associated with a significant risk of opportunistic infections, predominantly Pneumocystis Carinii pneumonia (PCP) requiring routine prophylaxis." | 5.09 | Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders. ( Fox, RM; Grigg, AP; Seymour, JF; Szer, J, 2001) |
| "Mitoxantrone (MTZ) and vinorelbine (VNR) have shown a good efficacy in advanced breast cancer." | 5.08 | Mitoxantrone plus vinorelbine with granulocyte-colony stimulating factor (G-CSF) support in advanced breast cancer patients. A dose and schedule finding study. ( Comella, G; Comella, P; Cremone, L; Della Volpe, N; Frasci, G; Imbriani, A; Persico, G; Salzano, F, 1995) |
| "To assess efficacy and toxicity of less toxic analogs for advanced breast cancer in elderly women, we performed a phase II study using the combination mitoxantrone (MTZ)-vinorelbine (VNR)." | 5.08 | [A phase II study with mitoxantrone-vinorelbine association in the treatment of advanced breast cancer in elderly women]. ( Bugat, R; Caunes, N; Chevreau, C; Gladieff, L; Houyau, P; Martinez, M; Mihura, J; Roché, H, 1996) |
| "60 patients with metastatic breast cancer were entered in a phase II study using folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide." | 5.07 | Folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide in metastatic breast cancer. ( Beerblock, K; de Gramont, A; Demuynck, B; Guillot, T; Krulik, M; Louvet, C; Marpeau, L; Pigné, A; Soubrane, D; Varette, C, 1993) |
| "Mitoxantrone is used for aggressive multiple sclerosis (MS), but concerns about safety, including cardiotoxicity and other laboratory measures, prevail." | 3.76 | Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. ( Geddes, J; Isserow, S; Kingwell, E; Koch, M; Leung, B; Rieckmann, P; Tremlett, H, 2010) |
| " The objective of the current study was to investigate the effects of combined fludarabine, mitoxantrone, and dexamethasone (FND) followed by interferon/dexamethasone on myelosuppression (absolute neutrophil counts), immunosuppression (CD4 and CD8 counts), and infectious complications in patients with previously untreated, Stage IV indolent lymphoma." | 3.73 | Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. ( Ayala, A; Cabanillas, F; Feng, L; Hagemeister, FB; McLaughlin, P; Rodriguez, MA; Romaguera, J; Smith, TL; Tsimberidou, AM; Younes, A, 2005) |
| "Cabazitaxel is a novel tubulin-binding taxane drug with antitumour activity in docetaxel-resistant cancers." | 2.75 | Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. ( Bodrogi, I; de Bono, JS; Gravis, G; Gupta, S; Hansen, S; Kocak, I; Machiels, JP; Mackenzie, MJ; Oudard, S; Ozguroglu, M; Roessner, M; Sartor, AO; Shen, L, 2010) |
| "In this prospective randomized trial, we compared the efficacy and toxicity of cladribine (2-CdA) alone to 2-CdA combined with cyclophosphamide (CC) or cyclophosphamide and mitoxantrone (CMC) in untreated progressive chronic lymphocytic leukemia (CLL)." | 2.72 | Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG C ( Blonski, JZ; Calbecka, M; Ceglarek, B; Dmoszynska, A; Dwilewicz-Trojaczek, J; Gora-Tybor, J; Jamroziak, K; Kasznicki, M; Kloczko, J; Konopka, L; Kowal, M; Kuliczkowski, K; Robak, T; Skotnicki, AB; Stella-Holowiecka, B; Sulek, K; Tomaszewska, A; Warzocha, K; Zawilska, K, 2006) |
| "Acute renal failure and bacterial infection occurred as non-hematologic dose limiting toxicities." | 2.70 | A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation. ( de Magalhaes-Silverman, M; Gingrich, RD; Hayashi, M; Hohl, RJ; Lee, CK; Schlueter, A; Strauss, RG, 2002) |
| " However, some trials showed that increasing the dosage of anthracyclines within induction therapy improved treatment outcome substantially." | 2.70 | Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years. ( Aulitzky, W; Bodenstein, H; Clemens, M; Ehninger, G; Illmer, T; Neubauer, A; Repp, R; Schaich, M; Schäkel, U; Soucek, S; Wandt, H, 2002) |
| " The maximal acceptable dosage of mitoxantrone was 10 mg/m2 x 2 due to serious hematologic toxicity." | 2.69 | Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma. ( Berinstein, NL; Franssen, E; Haq, R; Sawka, CA, 1999) |
| "Mitoxantrone (Novantrone) is an anthracene derivative that has demonstrated antitumor activity in patients with breast cancer, ovarian cancer, acute leukemia, and lymphoma." | 2.69 | A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors. ( Bigley, J; Burris, HA; Dieras, V; Eckardt, JR; Hardy, J; Hohneker, J; Jones, SF; Peacock, NW; Rodriguez, GI; Smith, L; Von Hoff, DD, 1998) |
| "Grade 3/4 neutropenia was observed in 29 patients (58%) with four neutropenic episodes." | 2.69 | First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin. ( Agelaki, S; Androulakis, N; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Koukourakis, M; Kourousis, C; Samonis, G; Tsiftsis, D; Vamvakas, L, 1999) |
| " Because its toxicities are minimal and do not overlap with the toxicities of standard chemotherapy, it is an appealing agent to use in combination with chemotherapy." | 2.69 | Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. ( Cabanillas, F; Dang, NH; Hagemeister, FB; Lee, MS; McAda, N; McLaughlin, P; Pate, O; Preti, AH; Rodriguez, MA; Romaguera, JE; Sarris, AH; Younes, A, 2000) |
| "All patients had advanced metastatic breast cancer and have been extensively pretreated with chemotherapy (28 patients), radiotherapy (13 patients), and hormonotherapy (24 patients)." | 2.68 | Treatment of advanced and relapsing breast cancer with a combination of paclitaxel and mitoxantrone. South-Central Hellenic Oncology Group. ( Panagos, GE, 1997) |
| "67 patients with relapsed or resistant multiple myeloma were randomized to receive either VAD (vincristine, doxorubicin, dexamethasone) or MOD (mitozantrone, vincristine, dexamethasone)." | 2.68 | A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma. ( Cawley, JC; Davies, JM; Newland, AC; Pearce, R; Phillips, JK; Reilly, JT; Sherlaw-Johnson, C, 1995) |
| " Ten dogs were given mitoxantrone at a dosage of 5." | 2.67 | Toxicoses associated with the administration of mitoxantrone to dogs with malignant tumors: a dose escalation study. ( Atwater, SW; Bergman, PJ; Chen, C; Ciekot, PA; Moore, AS; Ogilvie, GK; Walters, LM, 1994) |
| "Patients with advanced breast cancer were randomised to 3M (mitozantrone 6." | 2.67 | Mitozantrone and methotrexate chemotherapy with and without mitomycin C in the treatment of advanced breast cancer: a randomised clinical trial. ( Barton, C; Bliss, JM; Bower, M; Coombes, RC; Ford, HT; Gazet, JC; Law, M; Stein, RC, 1992) |
| "132 patients with advanced recurrent breast cancer were treated with four courses of mitozantrone 14 mg/m2 intravenously every 3 weeks (9 weeks)." | 2.67 | Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. ( Cantwell, BM; Carmichael, J; Dawes, P; Evans, RG; Farndon, J; Ghani, S; Harris, AL; Wilson, R, 1990) |
| " Neutropenia is the most common toxicity associated with mitoxantone therapy and may necessitate dosage reduction in some patients." | 2.40 | Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer. ( Spencer, CM; Wiseman, LR, 1997) |
| "A disseminated Fusarium infection due to F." | 1.39 | Refractory disseminated fusariosis by Fusarium verticillioides in a patient with acute myeloid leukaemia relapsed after allogeneic hematopoietic stem cell transplantation: a case report and literature review. ( Bartolesi, AM; Fanci, R; Pecile, P; Pini, G, 2013) |
| "Neutropenia was present in 74." | 1.32 | Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93. ( Creutzig, U; Kaiser, J; Klingebiel, T; Lehrnbecher, T; Reinhardt, D; Varwig, D, 2004) |
| "As compared with metastatic breast cancer (MBC), high risk breast cancer showed a 2." | 1.31 | Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy. ( Barbaro, P; Console, G; Iacopino, P; Irrera, G; Martino, M; Messina, G; Morabito, F; Oliva, E; Palazzo, S; Pucci, G, 2001) |
| "Severe infections are a major problem in patients suffering from acute nonlymphocytic leukemia (ANLL) undergoing myeloablative chemotherapy." | 1.30 | Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia. ( Diehl, V; Engert, A; Hegener, K; Hübel, K; Mansmann, G; Oberhäuser, F; Schnell, R; Staib, P, 1999) |
| "Mucormycosis is a rare fungal infection that has been described mainly in oncologic and diabetic patients." | 1.29 | [Pulmonary mucormycosis in leukemic patients. Apropos of 2 cases]. ( Cancelas, JA; Cerveró, C; García-Laraña, J; López, J; Navarro, JL; Odriozola, J; Pérez-Oteyza, J; Sánchez-Sousa, A; Sastre, JL, 1994) |
| "Neutropenic fever has been one of the most difficult complications in the recovery period following high-dose chemotherapy and autologous haematopoietic progenitor cell transplantation." | 1.29 | Neutropenic fever in patients after high-dose chemotherapy followed by autologous haematopoietic progenitor cell transplantation and human recombinant granulocyte-macrophage colony stimulating factor. ( Gagnon, A; Glück, S, 1994) |
| "Myelosuppression with subsequent infections was the major toxicity of this regimen." | 1.28 | Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin's lymphoma. ( del Valle, F; Dörken, B; Hiddemann, W; Ho, AD; Hunstein, W; Meusers, P; Rückle, H; Schlimok, G; Schwammborn, J; Thiel, E, 1989) |
| "Mitoxantrone is an active well-tolerated agent in the treatment of advanced breast carcinoma, but the risk of neutropenia requires careful supervision." | 1.27 | Mitoxantrone: an active new agent in the treatment of advanced breast cancer. ( Bozek, T; Pavlidis, NA; Smith, IE; Stuart-Harris, RC, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (4.55) | 18.7374 |
| 1990's | 39 (44.32) | 18.2507 |
| 2000's | 34 (38.64) | 29.6817 |
| 2010's | 11 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kimura, S | 1 |
| Wada, H | 1 |
| Ishihara, Y | 1 |
| Kawamura, K | 1 |
| Sakamoto, K | 1 |
| Yamasaki, R | 1 |
| Ashizawa, M | 1 |
| Machishima, T | 1 |
| Sato, M | 1 |
| Terasako, K | 1 |
| Nakasone, H | 1 |
| Kikuchi, M | 1 |
| Okuda, S | 1 |
| Kako, S | 1 |
| Kanda, J | 1 |
| Yamazaki, R | 1 |
| Tanihara, A | 1 |
| Nishida, J | 1 |
| Kanda, Y | 1 |
| Abrisqueta, P | 1 |
| Villamor, N | 1 |
| Terol, MJ | 1 |
| González-Barca, E | 1 |
| González, M | 1 |
| Ferrà, C | 1 |
| Abella, E | 1 |
| Delgado, J | 1 |
| García-Marco, JA | 1 |
| González, Y | 1 |
| Carbonell, F | 1 |
| Ferrer, S | 1 |
| Monzó, E | 1 |
| Jarque, I | 1 |
| Muntañola, A | 1 |
| Constants, M | 1 |
| Escoda, L | 1 |
| Calvo, X | 1 |
| Bobillo, S | 1 |
| Montoro, JB | 1 |
| Montserrat, E | 1 |
| Bosch, F | 1 |
| Meisel, A | 1 |
| von Felten, S | 1 |
| Vogt, DR | 1 |
| Liewen, H | 1 |
| de Wit, R | 1 |
| de Bono, J | 1 |
| Sartor, O | 1 |
| Stenner-Liewen, F | 1 |
| Munir, T | 1 |
| Howard, DR | 1 |
| McParland, L | 1 |
| Pocock, C | 1 |
| Rawstron, AC | 1 |
| Hockaday, A | 1 |
| Varghese, A | 1 |
| Hamblin, M | 1 |
| Bloor, A | 1 |
| Pettitt, A | 1 |
| Fegan, C | 1 |
| Blundell, J | 1 |
| Gribben, JG | 1 |
| Phillips, D | 1 |
| Hillmen, P | 1 |
| Deenik, W | 1 |
| Beverloo, HB | 1 |
| van der Poel-van de Luytgaarde, SC | 1 |
| Wattel, MM | 1 |
| van Esser, JW | 1 |
| Valk, PJ | 1 |
| Cornelissen, JJ | 1 |
| Braess, J | 1 |
| Spiekermann, K | 1 |
| Staib, P | 3 |
| Grüneisen, A | 1 |
| Wörmann, B | 4 |
| Ludwig, WD | 2 |
| Serve, H | 1 |
| Reichle, A | 1 |
| Peceny, R | 1 |
| Oruzio, D | 1 |
| Schmid, C | 1 |
| Schiel, X | 1 |
| Hentrich, M | 1 |
| Sauerland, C | 1 |
| Unterhalt, M | 1 |
| Fiegl, M | 1 |
| Kern, W | 2 |
| Buske, C | 1 |
| Bohlander, S | 1 |
| Heinecke, A | 2 |
| Baurmann, H | 1 |
| Beelen, DW | 1 |
| Berdel, WE | 1 |
| Büchner, T | 4 |
| Hiddemann, W | 5 |
| McHayleh, W | 1 |
| Sehgal, R | 1 |
| Redner, RL | 1 |
| Raptis, A | 1 |
| Agha, M | 1 |
| Natale, J | 1 |
| Luong, TM | 1 |
| Schlesselman, JJ | 1 |
| Foon, KA | 1 |
| Boyiadzis, M | 1 |
| Kingwell, E | 1 |
| Koch, M | 1 |
| Leung, B | 1 |
| Isserow, S | 1 |
| Geddes, J | 1 |
| Rieckmann, P | 1 |
| Tremlett, H | 1 |
| Godley, LA | 1 |
| Njiaju, UO | 1 |
| Green, M | 1 |
| Weiner, H | 1 |
| Lin, S | 1 |
| Odenike, O | 1 |
| Rich, ES | 1 |
| Artz, A | 1 |
| Van Besien, K | 1 |
| Daugherty, CK | 1 |
| Zhang, Y | 1 |
| Le Beau, MM | 1 |
| Stock, W | 1 |
| Larson, RA | 1 |
| Derbel, O | 1 |
| Cannas, G | 1 |
| Le, QH | 1 |
| Elhamri, M | 1 |
| Chelghoum, Y | 1 |
| Nicolas-Virelizier, E | 1 |
| Nicolini, F | 1 |
| Troncy, J | 1 |
| Barraco, F | 1 |
| Michallet, M | 1 |
| Thomas, X | 1 |
| de Bono, JS | 1 |
| Oudard, S | 1 |
| Ozguroglu, M | 1 |
| Hansen, S | 1 |
| Machiels, JP | 1 |
| Kocak, I | 1 |
| Gravis, G | 1 |
| Bodrogi, I | 1 |
| Mackenzie, MJ | 1 |
| Shen, L | 1 |
| Roessner, M | 1 |
| Gupta, S | 1 |
| Sartor, AO | 1 |
| Vehreschild, MJ | 1 |
| Meissner, AM | 1 |
| Cornely, OA | 1 |
| Maschmeyer, G | 3 |
| Neumann, S | 1 |
| von Lilienfeld-Toal, M | 1 |
| Karthaus, M | 1 |
| Wattad, M | 1 |
| Hellmich, M | 1 |
| Christ, H | 1 |
| Vehreschild, JJ | 1 |
| Saini, L | 1 |
| Minden, MD | 1 |
| Schuh, AC | 1 |
| Yee, KW | 1 |
| Schimmer, AD | 1 |
| Gupta, V | 1 |
| Atenafu, EG | 1 |
| Murray, C | 1 |
| Nixon, S | 1 |
| Brandwein, JM | 1 |
| Fanci, R | 1 |
| Pini, G | 1 |
| Bartolesi, AM | 1 |
| Pecile, P | 1 |
| Schaich, M | 1 |
| Illmer, T | 1 |
| Aulitzky, W | 1 |
| Bodenstein, H | 1 |
| Clemens, M | 1 |
| Neubauer, A | 1 |
| Repp, R | 1 |
| Schäkel, U | 1 |
| Soucek, S | 1 |
| Wandt, H | 1 |
| Ehninger, G | 1 |
| Lee, CK | 1 |
| de Magalhaes-Silverman, M | 1 |
| Hayashi, M | 1 |
| Schlueter, A | 1 |
| Strauss, RG | 1 |
| Hohl, RJ | 1 |
| Gingrich, RD | 1 |
| Lehrnbecher, T | 2 |
| Varwig, D | 1 |
| Kaiser, J | 1 |
| Reinhardt, D | 2 |
| Klingebiel, T | 1 |
| Creutzig, U | 2 |
| Lyman, GH | 1 |
| Delgado, DJ | 2 |
| Löfgren, C | 2 |
| Paul, C | 2 |
| Aström, M | 1 |
| Hast, R | 1 |
| Hedenius, M | 1 |
| Lerner, R | 1 |
| Liliemark, J | 1 |
| Nilsson, I | 1 |
| Rödjer, S | 1 |
| Simonsson, B | 1 |
| Stockelberg, D | 1 |
| Tidefelt, U | 2 |
| Björkholm, M | 1 |
| Hendry, L | 1 |
| Bowen, A | 1 |
| Matutes, E | 1 |
| Swansbury, J | 1 |
| Catovsky, D | 1 |
| Sheen, WC | 1 |
| Chen, JS | 1 |
| Wang, HM | 1 |
| Yang, TS | 1 |
| Liaw, CC | 1 |
| Lin, YC | 1 |
| Wöhrer, S | 1 |
| Raderer, M | 1 |
| Kaufmann, H | 1 |
| Hejna, M | 1 |
| Chott, A | 1 |
| Zielinski, CC | 1 |
| Drach, J | 1 |
| Ishii, K | 1 |
| Yamamoto, Y | 1 |
| Shigeki, T | 1 |
| Kitayama, H | 1 |
| Hayashi, K | 1 |
| Hirose, A | 1 |
| Ohta, T | 1 |
| Mugitani, A | 1 |
| Fujino, H | 1 |
| Yagi, T | 1 |
| Hirai, M | 1 |
| Teshima, H | 1 |
| Katsurada, T | 1 |
| Urase, F | 1 |
| Kitajima, H | 1 |
| Tsimberidou, AM | 1 |
| Younes, A | 2 |
| Romaguera, J | 1 |
| Hagemeister, FB | 2 |
| Rodriguez, MA | 2 |
| Feng, L | 1 |
| Ayala, A | 1 |
| Smith, TL | 1 |
| Cabanillas, F | 2 |
| McLaughlin, P | 2 |
| Schmid, P | 1 |
| Flath, B | 1 |
| Akrivakis, K | 1 |
| Heilmann, V | 1 |
| Mergenthaler, HG | 1 |
| Sezer, O | 1 |
| Kreienberg, R | 1 |
| Possinger, K | 1 |
| Chamorey, E | 1 |
| Gressin, R | 1 |
| Peyrade, F | 1 |
| Rossi, JF | 1 |
| Lepeu, G | 1 |
| Foussard, C | 1 |
| Harrousseau, JL | 1 |
| Fabbro, M | 1 |
| Richard, B | 1 |
| Delwail, V | 1 |
| Maisonneuve, H | 1 |
| Vilque, JP | 2 |
| Thyss, A | 1 |
| Robak, T | 1 |
| Blonski, JZ | 1 |
| Gora-Tybor, J | 1 |
| Jamroziak, K | 1 |
| Dwilewicz-Trojaczek, J | 1 |
| Tomaszewska, A | 1 |
| Konopka, L | 1 |
| Ceglarek, B | 1 |
| Dmoszynska, A | 1 |
| Kowal, M | 1 |
| Kloczko, J | 1 |
| Stella-Holowiecka, B | 1 |
| Sulek, K | 1 |
| Calbecka, M | 1 |
| Zawilska, K | 1 |
| Kuliczkowski, K | 1 |
| Skotnicki, AB | 1 |
| Warzocha, K | 1 |
| Kasznicki, M | 1 |
| Zimmermann, M | 1 |
| Graf, N | 1 |
| Hermann, J | 1 |
| Niemeyer, CM | 1 |
| Reiter, A | 1 |
| Ritter, J | 1 |
| Dworzak, M | 1 |
| Stary, J | 1 |
| Awan, F | 1 |
| Hamadani, M | 1 |
| Devine, S | 1 |
| Zinzani, PL | 1 |
| Tani, M | 1 |
| Fanti, S | 1 |
| Stefoni, V | 1 |
| Musuraca, G | 1 |
| Vitolo, U | 1 |
| Perrotti, A | 1 |
| Fina, M | 1 |
| Derenzini, E | 1 |
| Baccarani, M | 1 |
| Errante, D | 1 |
| Bianco, A | 1 |
| Aversa, SML | 1 |
| Salvagno, L | 1 |
| Valdivieso, M | 1 |
| Umsawasdi, T | 1 |
| Spitzer, G | 2 |
| Chiuten, DF | 1 |
| Booser, DJ | 1 |
| Dhingra, HM | 1 |
| Bodey, GP | 1 |
| Smith, IE | 2 |
| Stuart-Harris, RC | 1 |
| Bozek, T | 1 |
| Pavlidis, NA | 1 |
| Dinçol, D | 1 |
| Içli, F | 1 |
| Karaoğuz, H | 1 |
| Cay, F | 1 |
| Arican, A | 1 |
| Demirkazik, A | 1 |
| Akbulut, H | 1 |
| Di Leo, A | 1 |
| Bajetta, E | 1 |
| Nolè, F | 1 |
| Biganzoli, L | 1 |
| Ferrari, L | 1 |
| Oriana, S | 1 |
| Riboldi, G | 1 |
| Bohm, S | 1 |
| Spatti, G | 1 |
| Raspagliesi, F | 1 |
| Sastre, JL | 1 |
| Pérez-Oteyza, J | 1 |
| López, J | 1 |
| Cerveró, C | 1 |
| Sánchez-Sousa, A | 1 |
| García-Laraña, J | 1 |
| Cancelas, JA | 1 |
| Odriozola, J | 1 |
| Navarro, JL | 1 |
| Frasci, G | 1 |
| Comella, G | 1 |
| Comella, P | 1 |
| Salzano, F | 1 |
| Cremone, L | 1 |
| Della Volpe, N | 1 |
| Imbriani, A | 1 |
| Persico, G | 1 |
| Phillips, JK | 1 |
| Sherlaw-Johnson, C | 1 |
| Pearce, R | 1 |
| Davies, JM | 1 |
| Reilly, JT | 1 |
| Newland, AC | 1 |
| Cawley, JC | 1 |
| Schönbohn, H | 1 |
| Schuler, M | 1 |
| Kolbe, K | 1 |
| Peschel, C | 1 |
| Huber, C | 1 |
| Bemb, W | 1 |
| Aulitzky, WE | 1 |
| Bezwoda, WR | 1 |
| Seymour, L | 1 |
| Dansey, RD | 1 |
| Kantarjian, HM | 1 |
| Estey, E | 1 |
| O'Brien, S | 1 |
| Anaissie, E | 1 |
| Beran, M | 1 |
| Pierce, S | 1 |
| Robertson, L | 1 |
| Keating, MJ | 1 |
| Patrone, F | 1 |
| Ballestrero, A | 1 |
| Ferrando, F | 1 |
| Brema, F | 1 |
| Moraglio, L | 1 |
| Valbonesi, M | 1 |
| Basta, P | 1 |
| Ghio, R | 1 |
| Gobbi, M | 1 |
| Sessarego, M | 1 |
| Glück, S | 1 |
| Gagnon, A | 1 |
| Dunphy, FR | 1 |
| Petruska, PJ | 1 |
| Velasquez, WS | 1 |
| Adkins, DR | 1 |
| Ogilvie, GK | 1 |
| Moore, AS | 1 |
| Chen, C | 1 |
| Ciekot, PA | 1 |
| Atwater, SW | 1 |
| Bergman, PJ | 1 |
| Walters, LM | 1 |
| Damon, LE | 1 |
| Rugo, HS | 1 |
| Ries, CA | 1 |
| Linker, CA | 1 |
| Louvet, C | 1 |
| de Gramont, A | 1 |
| Demuynck, B | 1 |
| Beerblock, K | 1 |
| Varette, C | 1 |
| Soubrane, D | 1 |
| Marpeau, L | 1 |
| Pigné, A | 1 |
| Guillot, T | 1 |
| Krulik, M | 1 |
| Ansell, SM | 1 |
| Falkson, G | 1 |
| Maslak, PG | 1 |
| Weiss, MA | 1 |
| Berman, E | 1 |
| Yao, TJ | 1 |
| Tyson, D | 1 |
| Golde, DW | 1 |
| Scheinberg, DA | 1 |
| Gillis, S | 1 |
| Dann, EJ | 1 |
| Rund, D | 1 |
| Hsu, HC | 1 |
| Chiu, CF | 1 |
| Tan, TD | 1 |
| Chau, WK | 1 |
| Tseng, CS | 1 |
| Ho, CH | 1 |
| Fleming, GF | 1 |
| Janisch, L | 1 |
| Vogelzang, NJ | 1 |
| Vokes, EE | 1 |
| Ratain, MJ | 1 |
| Gladieff, L | 1 |
| Houyau, P | 1 |
| Mihura, J | 1 |
| Martinez, M | 1 |
| Caunes, N | 1 |
| Chevreau, C | 1 |
| Bugat, R | 1 |
| Roché, H | 1 |
| Olalla, I | 1 |
| Ortín, M | 1 |
| Hermida, G | 1 |
| Cortés, MA | 1 |
| Richard, C | 1 |
| Iriondo, A | 1 |
| Mozota, ML | 1 |
| Zubizarreta, A | 1 |
| Panagos, GE | 1 |
| Brodsky, AL | 1 |
| Melero, MJ | 1 |
| Minissale, CJ | 1 |
| Sánchez Avalos, JC | 1 |
| Wiseman, LR | 1 |
| Spencer, CM | 1 |
| Wang, WS | 1 |
| Tzeng, CH | 1 |
| Chiou, TJ | 1 |
| Liu, JH | 1 |
| Hsieh, RK | 1 |
| Yen, CC | 1 |
| Chen, PM | 1 |
| Peacock, NW | 1 |
| Burris, HA | 1 |
| Dieras, V | 1 |
| Smith, L | 1 |
| Rodriguez, GI | 1 |
| Eckardt, JR | 1 |
| Jones, SF | 1 |
| Hardy, J | 1 |
| Hohneker, J | 1 |
| Bigley, J | 1 |
| Von Hoff, DD | 1 |
| Aul, C | 2 |
| Kuse, R | 1 |
| Kerkhoff, A | 1 |
| Grote-Metke, A | 1 |
| Eimermacher, H | 1 |
| Kubica, U | 1 |
| Möllgård, L | 1 |
| Sundman-Engberg, B | 1 |
| Lehman, S | 1 |
| Kouroussis, C | 2 |
| Androulakis, N | 2 |
| Kakolyris, S | 3 |
| Souglakos, J | 1 |
| Kotsakis, T | 1 |
| Mavroudis, D | 2 |
| Katsogridakis, K | 1 |
| Vardakis, N | 1 |
| Hatzidaki, D | 2 |
| Samonis, G | 2 |
| Vlachonikolis, J | 1 |
| Georgoulias, V | 3 |
| Hübel, K | 1 |
| Hegener, K | 1 |
| Schnell, R | 1 |
| Mansmann, G | 1 |
| Oberhäuser, F | 1 |
| Diehl, V | 1 |
| Engert, A | 1 |
| Martino, R | 1 |
| Guardia, R | 1 |
| Altés, A | 1 |
| Sureda, A | 1 |
| Brunet, S | 1 |
| Sierra, J | 1 |
| Verbeek, W | 1 |
| Koch, P | 1 |
| Hinrichs, HF | 1 |
| Balleisen, L | 1 |
| Rowe, JM | 1 |
| Bennett, J | 1 |
| Haase, D | 1 |
| Fonatsch, C | 1 |
| Kourousis, C | 1 |
| Koukourakis, M | 1 |
| Vamvakas, L | 1 |
| Agelaki, S | 2 |
| Tsiftsis, D | 1 |
| Haq, R | 1 |
| Sawka, CA | 1 |
| Franssen, E | 1 |
| Berinstein, NL | 1 |
| Harousseau, JL | 1 |
| Witz, B | 1 |
| Lioure, B | 1 |
| Hunault-Berger, M | 1 |
| Desablens, B | 1 |
| Delain, M | 1 |
| Guilhot, F | 1 |
| Le Prise, PY | 1 |
| Abgrall, JF | 1 |
| Deconinck, E | 1 |
| Guyotat, D | 1 |
| Casassus, P | 1 |
| Tournilhac, O | 1 |
| Audhuy, B | 1 |
| Solary, E | 1 |
| Sternberg, DW | 1 |
| Aird, W | 1 |
| Neuberg, D | 1 |
| Thompson, L | 1 |
| MacNeill, K | 1 |
| Amrein, P | 1 |
| Shulman, LN | 1 |
| Patnaik, A | 1 |
| MacKinnon, J | 1 |
| Goss, P | 1 |
| Nagy, T | 1 |
| Stewart, K | 1 |
| Keating, A | 1 |
| Crump, M | 1 |
| Sarris, AH | 1 |
| Pate, O | 1 |
| Lee, MS | 1 |
| Dang, NH | 1 |
| Romaguera, JE | 1 |
| Preti, AH | 1 |
| McAda, N | 1 |
| Weiss, M | 1 |
| Thurnher, D | 1 |
| Kornfehl, J | 2 |
| Burian, M | 2 |
| Gedlicka, C | 2 |
| Selzer, E | 2 |
| Quint, C | 1 |
| Neuchrist, C | 1 |
| Kornek, GV | 2 |
| Harvey, J | 1 |
| Cantrell, J | 1 |
| Campbell, M | 1 |
| Cartmell, A | 1 |
| Urba, W | 1 |
| Modiano, M | 1 |
| Schuster, M | 1 |
| Rubin, A | 1 |
| Newcomb, T | 1 |
| Ghalie, R | 1 |
| Alexopoulos, A | 1 |
| Malamos, N | 1 |
| Kalbakis, K | 1 |
| Kosmas, C | 1 |
| Vlachonicolis, J | 1 |
| Sarra, E | 1 |
| Rigatos, G | 1 |
| Picozzi, VJ | 1 |
| Pohlman, BL | 1 |
| Morrison, VA | 1 |
| Lawless, GD | 1 |
| Lee, MW | 1 |
| Kerr, RO | 1 |
| Ford, JM | 1 |
| Fridman, M | 1 |
| Carter, WB | 1 |
| Seymour, JF | 1 |
| Grigg, AP | 1 |
| Szer, J | 1 |
| Fox, RM | 1 |
| Morabito, F | 1 |
| Irrera, G | 1 |
| Oliva, E | 1 |
| Console, G | 1 |
| Martino, M | 1 |
| Pucci, G | 1 |
| Messina, G | 1 |
| Barbaro, P | 1 |
| Palazzo, S | 1 |
| Iacopino, P | 1 |
| Dimopoulos, MA | 2 |
| Fountzilas, G | 2 |
| Papageorgiou, E | 1 |
| Kiamouris, C | 1 |
| Mantzios, G | 1 |
| Anagnostopoulos, A | 1 |
| Nicolaides, C | 2 |
| Economopoulos, T | 2 |
| Schüll, B | 1 |
| Formanek, M | 1 |
| Knerer, B | 1 |
| Scheithauer, W | 1 |
| Mellou, S | 1 |
| Pavlidis, N | 1 |
| Samantas, E | 1 |
| Tsatalas, C | 1 |
| Papadopoulos, A | 1 |
| Papageogriou, E | 1 |
| Papasavvas, P | 1 |
| Stein, RC | 1 |
| Bower, M | 1 |
| Law, M | 1 |
| Bliss, JM | 1 |
| Barton, C | 1 |
| Gazet, JC | 1 |
| Ford, HT | 1 |
| Coombes, RC | 1 |
| Gherlinzoni, F | 1 |
| Guglielmi, C | 1 |
| Mazza, P | 1 |
| Amadori, S | 1 |
| Mandelli, F | 1 |
| Tura, S | 1 |
| Koenigsmann, M | 1 |
| Zühlsdorf, M | 1 |
| Boeckmann, A | 1 |
| Freire, EA | 1 |
| Innig, G | 1 |
| Harris, AL | 1 |
| Cantwell, BM | 1 |
| Carmichael, J | 1 |
| Wilson, R | 1 |
| Farndon, J | 1 |
| Dawes, P | 1 |
| Ghani, S | 1 |
| Evans, RG | 1 |
| Rogers, S | 1 |
| Potter, MN | 1 |
| Slade, RR | 1 |
| Ho, AD | 1 |
| del Valle, F | 1 |
| Rückle, H | 1 |
| Schwammborn, J | 1 |
| Schlimok, G | 1 |
| Meusers, P | 1 |
| Thiel, E | 1 |
| Dörken, B | 1 |
| Hunstein, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Stereotactic Body Radiotherapy (SBRT) and Stereotactic Hypofractionated Radiotherapy (SHRT) for Oligometastatic Prostate Cancer[NCT01859221] | 39 participants (Actual) | Interventional | 2013-05-31 | Completed | |||
| Prospective Pilot Clinical Trial of Ac225-PSMA Radioligand Therapy of Metastatic Castration-resistant Prostate Cancer[NCT04225910] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2020-01-01 | Not yet recruiting | ||
| Predictive fActors for toleraNce to Taxane Based CHemotherapy In Older adultS Affected by mEtastatic Prostate Cancer, a Prospective Observational Study (ANCHISES)[NCT05471427] | 118 participants (Actual) | Observational | 2020-01-01 | Completed | |||
| A Randomized Phase II Trial Comparing Biomarker Directed Therapy Versus Clinician's Choice of Enzalutamide or Docetaxel in Patients With Advanced Prostate Cancer Post Abiraterone[NCT04015622] | Phase 2 | 100 participants (Anticipated) | Interventional | 2020-10-07 | Recruiting | ||
| A Phase I/II Study of Alisertib in Combination With Abiraterone and Prednisone for Patients With Castration-Resistant Prostate Cancer After Progression on Abiraterone[NCT01848067] | Phase 1/Phase 2 | 9 participants (Actual) | Interventional | 2013-08-14 | Completed | ||
| A Randomized, Open Label Multi-Center Study of XRP6258 at 25 mg/m^2 in Combination With Prednisone Every 3 Weeks Compared to Mitoxantrone in Combination With Prednisone For The Treatment of Hormone Refractory Metastatic Prostate Cancer Previously Treated [NCT00417079] | Phase 3 | 755 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| A Phase I Study of Entinostat in Combination With Enzalutamide for Treatment of Patients With Castration-Resistant Prostate Cancer[NCT03829930] | Phase 1 | 6 participants (Actual) | Interventional | 2019-05-01 | Terminated (stopped due to Sponsor discontinued the drug) | ||
| Phase I Study of Cabazitaxel - Platinum Fluorouracil Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck[NCT01379339] | Phase 1 | 40 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| A Randomized Phase II Study of OGX-427 (a Second-Generation Antisense Oligonucleotide to Heat Shock Protein-27) in Patients With Castration Resistant Prostate Cancer Who Have Not Previously Received Chemotherapy for Metastatic Disease[NCT01120470] | Phase 2 | 74 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Survival Outcomes in Metastatic Prostate Cancer in the Brazilian Population - Analysis of Individual Characteristics and Treatment Modalities in Different National Health Institutions.[NCT04962919] | 590 participants (Anticipated) | Observational | 2020-01-14 | Recruiting | |||
| An Open-label, Phase I/IIa Dose Escalation and Expansion Study to Determine the Safety and Clinical Activity of an Immune Priming Cell Therapy (INKmune) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)[NCT06056791] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2023-11-30 | Not yet recruiting | ||
| A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35)[NCT00779883] | Phase 1 | 9 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A Phase 1B Extension Trial to Allow Repeat Dosing of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) in Subjects Previously Treated in MDACC Protocol 2004-0914[NCT00783588] | Phase 1 | 4 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| A Pilot Study of Low Dose Melphalan and Bortezomib for Treatment of Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndromes[NCT00789256] | 26 participants (Actual) | Interventional | 2004-09-30 | Completed | |||
| A Prospective, Open, Randomized Controlled, Multi-center Phase III Clinical Trial Comparing High-dose Epirubicin and Standard-dose Epirubicin in R±CEOP in Newly Diagnosed Young Patients With Medium/High-risk Diffuse Large B-cell Lymphoma[NCT03151044] | Phase 3 | 408 participants (Anticipated) | Interventional | 2016-07-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Compared between the two patient subsets using the nonparametric Mann-Whitney test. A comparison of CTC counts between baseline and at progression for those who have progressed will be carried out using either a paired t test or the nonparameteric Wilcoxon matched pairs test. (NCT01848067)
Timeframe: Baseline up to 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Alisertib, Abiraterone Acetate, Prednisone) | 3 |
Summarized with descriptive statistics. (NCT01848067)
Timeframe: Up to 21 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Alisertib, Abiraterone Acetate, Prednisone) | 2 |
"Overall survival was defined as the time interval from the date of randomization to the date of death due to any cause.~In the absence of confirmation of death, the survival time was censored at the last date patient was known to be alive or at the cut-off date, whichever had come first." (NCT00417079)
Timeframe: From the date of randomization up to 104 weeks (study cut-off)
| Intervention | Months (Median) |
|---|---|
| Mitoxantrone + Prednisone | 12.7 |
| Cabazitaxel + Prednisone | 15.1 |
"Tumor Overall Response Rate (ORR) (only in patients with measurable disease):~Objective responses (Complete Response and Partial Response) for measurable disease as assessed by investigators according to RECIST criteria.~Complete Response (CR) is defined as: Disappearance of all target lesions. Partial Response (PR) is defined as: At least a 30% decrease in the sum of longest diameter (LD) of target lesions taking as reference baseline sum LD.~Confirmation of objective responses will be performed by repeat tumor imaging (CT scans, MRI, bone scans) after the first documentation of response." (NCT00417079)
Timeframe: From the date of randomization up to 104 weeks (study cut-off)
| Intervention | percentage of participants (Number) |
|---|---|
| Mitoxantrone + Prednisone | 4.4 |
| Cabazitaxel + Prednisone | 14.4 |
Pain Response was defined as a two-point or greater reduction from baseline median Present Pain Intensity (PPI) score without an increased Analgesic Score (AS) or a decrease of ≥50% in the AS without an increase in the PPI score, maintained for at least 3 weeks. (NCT00417079)
Timeframe: from baseline up to 104 weeks (study cut-off)
| Intervention | Percentage of participants (Number) |
|---|---|
| Mitoxantrone + Prednisone | 7.7 |
| Cabazitaxel + Prednisone | 9.2 |
PSA response was defined as a ≥ 50% reduction in serum PSA, determined only for patients with a serum PSA ≥ 20ng/mL at baseline, confirmed by a repeat PSA ≥ 3 weeks later. (NCT00417079)
Timeframe: from baseline up to 104 weeks (study cut-off)
| Intervention | Percentage of participants (Number) |
|---|---|
| Mitoxantrone + Prednisone | 17.8 |
| Cabazitaxel + Prednisone | 39.2 |
"Pain Progression is defined as an increase of ≥1 point in the median Personal Pain Intensity (PPI) from its nadir noted on 2 consecutive 3-week-apart visits or ≥25 % increase in the mean analgesic score compared with the baseline score & noted on 2 consecutive 3-week-apart visits or requirement for local palliative radiotherapy.~Evaluation of the PPI & analgesic scores are based on the short-form McGill Pain Questionnaire which consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0=none (best) 1=mild 2=moderate 3=severe (worst) (TOTAL: 0=best 45=worst)" (NCT00417079)
Timeframe: from baseline up to 104 weeks (study cut-off)
| Intervention | Months (Median) |
|---|---|
| Mitoxantrone + Prednisone | NA |
| Cabazitaxel + Prednisone | 11.1 |
Progression free survival was defined as a composite endpoint evaluated from the date of randomization to the date of tumor progression, PSA progression, pain progression, or death due to any cause, whichever occurred first (NCT00417079)
Timeframe: From the date of randomization up to 104 weeks (study cut-off)
| Intervention | Months (Median) |
|---|---|
| Mitoxantrone + Prednisone | 1.4 |
| Cabazitaxel + Prednisone | 2.8 |
"In PSA non-responders, progression will be defined as a 25% increase over nadir and increase in the absolute value PSA level by at least 5 ng/ml and confirmed by a second value at least 4 weeks later.~In PSA responders and in patients not evaluable for PSA response at baseline, progression will be defined as a ≥50% increase over nadir, provided that the increase is a minimum of 5 ng/ml and confirmed by a second value at least 1 week later." (NCT00417079)
Timeframe: at screening, day 1 of every treatment cycle, up to 104 weeks (study cut-off)
| Intervention | Months (Median) |
|---|---|
| Mitoxantrone + Prednisone | 3.1 |
| Cabazitaxel + Prednisone | 6.4 |
Time to tumor progression is defined as the number of months from randomization until evidence of progressive disease (RECIST) (NCT00417079)
Timeframe: From the date of randomization up to 104 weeks (study cut-off)
| Intervention | Months (Median) |
|---|---|
| Mitoxantrone + Prednisone | 5.4 |
| Cabazitaxel + Prednisone | 8.8 |
Determine disease response to treatment using Cheson 2000 report of an international working group to standardize response criteria for myelodysplastic syndromes. (NCT00789256)
Timeframe: Post Cycle 1 through 28 days post-treatment
| Intervention | participants (Number) |
|---|---|
| Strata 1 | 5 |
| Strata 2 | 2 |
4 reviews available for mitoxantrone and Neutropenia
| Article | Year |
|---|---|
Mitoxantrone (novantrone): a review of experimental and early clinical studies.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Doxorubi | 1983 |
Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer.
Topics: Antineoplastic Agents; Cardiovascular System; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; | 1997 |
High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Drug Administr | 1997 |
Induction therapy of adult acute lymphocytic leukemia without the use of vincristine or prednisone.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials | 2001 |
55 trials available for mitoxantrone and Neutropenia
| Article | Year |
|---|---|
Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Area U | 2013 |
Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Granulocyte Colony | 2016 |
Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival | 2017 |
Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabi | 2009 |
Mitoxantrone and etoposide in patients with newly diagnosed acute myeloid leukemia with persistent leukemia after a course of therapy with cytarabine and idarubicin.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; | 2009 |
Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Co | 2010 |
Clinically defined chemotherapy-associated bowel syndrome predicts severe complications and death in cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Incidence; Inflam | 2011 |
Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding | 2002 |
A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation.
Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cy | 2002 |
Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia: a Swedish multicentre randomized trial.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; | 2004 |
Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 2004 |
Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 2004 |
Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 2004 |
Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 2004 |
[VNCOP-B (etoposide, mitoxantrone, cyclophosphamide, vincristine, predonisolone, bleomycin) therapy in elderly patients with aggressive non-Hodgkin lymphoma--a study of efficacy and safety, final report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Drug Administrati | 2005 |
Gemcitabine and mitoxantrone in metastatic breast cancer: a phase-I-study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast | 2005 |
Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Disease-Free | 2005 |
Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG C
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclopho | 2006 |
Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; | 2006 |
A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Fem | 2008 |
Mitoxantrone (novantrone): a review of experimental and early clinical studies.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Doxorubi | 1983 |
The intramuscular administration of granulocyte colony-stimulating factor as an adjunct to chemotherapy in pretreated ovarian cancer patients: an Italian Trials in Medical Oncology (ITMO) Group pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Granulocyte Colony-S | 1994 |
Mitoxantrone plus vinorelbine with granulocyte-colony stimulating factor (G-CSF) support in advanced breast cancer patients. A dose and schedule finding study.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1995 |
A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Drug Resistance; F | 1995 |
High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant | 1995 |
Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modal | 1995 |
Toxicoses associated with the administration of mitoxantrone to dogs with malignant tumors: a dose escalation study.
Topics: Animals; Bone Marrow; Diarrhea; Dog Diseases; Dogs; Female; Follow-Up Studies; Leukocyte Count; Logi | 1994 |
Folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclo | 1993 |
A phase II trial of a chemotherapy combination in elderly patients with aggressive lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide | 1993 |
Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; | 1996 |
Post-remission intensive consolidation with high-dose cytarabine-based chemotherapy and granulocyte colony-stimulatory factor in adults with acute myelogenous leukemia: a preliminary report.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Gr | 1995 |
Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor support.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Granulocyte-Macrophage Colony-S | 1996 |
[A phase II study with mitoxantrone-vinorelbine association in the treatment of advanced breast cancer in elderly women].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pro | 1996 |
Treatment of advanced and relapsing breast cancer with a combination of paclitaxel and mitoxantrone. South-Central Hellenic Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiac Output, Low; | 1997 |
[Chemotherapy schedules and bacteremia in adult patients with acute leukemia].
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Anti | 1996 |
High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Drug Administr | 1997 |
A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male | 1998 |
Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Critical Car | 1998 |
High single dose of mitoxantrone and cytarabine in acute non-lymphocytic leukemia: a pharmacokinetic and clinical study.
Topics: Adult; Aged; Amsacrine; Chromatography, High Pressure Liquid; Cytarabine; Drug Administration Schedu | 1998 |
Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Respo | 1999 |
Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Combined Modality | 1999 |
Results of a randomized double-blind placebo-controlled trial evaluating sequential high-dose cytosine arabinoside/mitoxantrone chemotherapy with or without granulocyte/macrophage-colony-stimulating factor in high-risk myelodysplastic syndromes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Double-Blind Method; Evalua | 1999 |
First-line treatment of metastatic breast cancer with mitoxantrone, vinorelbine, and carboplatin.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplas | 1999 |
Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; D | 1999 |
Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques.
Topics: Acute Disease; Adolescent; Adult; Amsacrine; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; | 2000 |
Phase I/II trial of cyclophosphamide, mitoxantrone, and escalated doses of carboplatin supported by peripheral-blood stem cells in women with metastatic breast cancer.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cy | 2000 |
Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2000 |
Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Anemia; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2001 |
Mitoxantrone and paclitaxel combination chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; | 2001 |
Docetaxel in combination with mitoxantrone and granulocyte colony-stimulating factor as front-line chemotherapy in metastatic breast cancer: a multicenter phase II study.
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast | 2001 |
Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Hematopoietic Stem Cell Mobiliz | 2001 |
Primary treatment of low-grade non-Hodgkin's lymphoma with the combination of fludarabine and mitoxantrone: a phase II study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lymp | 2002 |
Mitoxantrone and cisplatin in recurrent and/or metastatic salivary gland malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dise | 2002 |
Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols | 2002 |
Mitozantrone and methotrexate chemotherapy with and without mitomycin C in the treatment of advanced breast cancer: a randomised clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Methotrexate; Midd | 1992 |
Phase III comparative trial (m-BACOD v m-BNCOD) in the treatment of stage II to IV non-Hodgkin's lymphomas with intermediate- or high-grade histology.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; | 1990 |
Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer.
Topics: Adult; Aged; Alopecia; Breast Neoplasms; Combined Modality Therapy; Doxorubicin; Drug Administration | 1990 |
31 other studies available for mitoxantrone and Neutropenia
| Article | Year |
|---|---|
D-index dose not predict the development of pulmonary infection in acute myeloid leukemia patients undergoing consolidation chemotherapy with high-dose cytarabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Consol | 2014 |
Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Combined Modality Therapy; Cytarabine; | 2009 |
Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.
Topics: Adult; Age Factors; Analgesics; Anemia; Female; Follow-Up Studies; Humans; Liver Diseases; Male; Mid | 2010 |
A single dose pegfilgrastim for supporting neutrophil recovery in patients treated for high-risk acute myeloid leukemia by the EMA 2000 schedule.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Eto | 2010 |
Feasibility of outpatient consolidation chemotherapy in older versus younger patients with acute myeloid leukemia.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Anti-Infective Agents; | 2012 |
Refractory disseminated fusariosis by Fusarium verticillioides in a patient with acute myeloid leukaemia relapsed after allogeneic hematopoietic stem cell transplantation: a case report and literature review.
Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Combined M | 2013 |
Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bacteria; Chi | 2004 |
Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemot | 2003 |
A modified low-dose regimen of mitoxantrone and prednisolone in patients with androgen-independent prostate cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Administrati | 2004 |
Effective treatment of indolent non-hodgkin's lymphomas with mitoxantrone, chlorambucil and prednisone.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Di | 2005 |
Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; CD4-CD8 Ratio; De | 2005 |
Paraneoplastic Sweet's syndrome and the pathergy phenomenon.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Diagnosis, Differential; Drug Eruptions; | 2007 |
Comment on: 'Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome'.
Topics: Administration, Oral; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Ble | 2008 |
Phase II clinical evaluation of dihydroxyanthracenedione in patients with advanced lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Anthraquinones; Antineoplastic Agents; Carcinoma, Small Cell; Carcinoma | 1984 |
Mitoxantrone: an active new agent in the treatment of advanced breast cancer.
Topics: Adult; Aged; Agranulocytosis; Anthraquinones; Breast Neoplasms; Doxorubicin; Drug Evaluation; Female | 1984 |
Mesna/ifosfamide, mitoxantrone, etoposide, bleomycin, vincristine, prednisone (MINE-BOP) combination chemotherapy in the treatment of refractory and relapsed non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cytar | 1995 |
[Pulmonary mucormycosis in leukemic patients. Apropos of 2 cases].
Topics: Adult; Aged; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Fatal Outco | 1994 |
Plasma levels of IL-1, TNF alpha, IL-6, IL-8, G-CSF, and IL1-RA during febrile neutropenia: results of a prospective study in patients undergoing chemotherapy for acute myelogenous leukemia.
Topics: Adolescent; Adult; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 1995 |
Granulocyte colony-stimulating factor supportive treatment following intensive chemotherapy in acute lymphocytic leukemia in first remission.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; H | 1993 |
Neutropenic fever in patients after high-dose chemotherapy followed by autologous haematopoietic progenitor cell transplantation and human recombinant granulocyte-macrophage colony stimulating factor.
Topics: Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Fever; Granulocyte-Macrophage Colony- | 1994 |
Tandem transplants in solid tumors: marrow versus peripheral stem cell transplant: peripheral blood cells as now practiced are not the whole answer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow Transplantation; Breas | 1993 |
Post-remission cytopenias following intense induction chemotherapy for acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marro | 1994 |
Selective discharge of patients with acute myeloid leukemia during chemotherapy-induced neutropenia.
Topics: Acute Disease; Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Bacterial Inf | 1996 |
Autologous peripheral blood stem cell transplantation in a patient with previous invasive middle ear mucormycosis.
Topics: Acute Disease; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Co | 1996 |
Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Fever | 1999 |
Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen.
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Com | 2000 |
Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-F | 2001 |
Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy.
Topics: Adult; Aged; Ambulatory Care; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Antineoplast | 2001 |
Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytar | 1991 |
Aspergillus appendicitis in acute myeloid leukaemia.
Topics: Adult; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Appendicitis; Appendix; Asper | 1990 |
Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation | 1989 |